Journal of Clinical Oncology 临床肿瘤· Baoqing Chen·· 2 天前AI 评分20
关于 Tislelizumab 联合放化疗治疗食管鳞癌的回复
Reply to: “Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration” and “NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002”
AI 导读
该文回复了关于 Tislelizumab 联合放化疗治疗食管鳞癌的治疗耐受性和随访时间的质疑,并讨论了 NRF2 通路状态与维持免疫治疗暴露的关系。
来源:Journal of Clinical Oncology 临床肿瘤 · ascopubs.org